Arena Pharmaceuticals to Announce First Quarter 2004 Financial Results on Tuesday, April 20, 2004, and to Host Conference Call and Webcast on Wednesday, April 21, 2004.Business Editors SAN DIEGO--(BUSINESS WIRE)--April 13, 2004 Arena Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ARNA) today announced that the company will release first quarter 2004 financial results after the NASDAQ National Market closes on Tuesday, April 20, 2004. Arena also announced today that Jack Lief, President and Chief Executive Officer of Arena, will host a conference call to discuss the financial results and corporate highlights from the first quarter. The call will take place on Wednesday, April 21, 2004, at 9:00 AM Eastern Time (6:00 AM Pacific Time). The conference call may be accessed by dialing (800) 450-0819 for domestic callers and (612) 332-0342 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals First Quarter Earnings Conference Call." The conference call will be webcast live on Arena's website at http://www.arenapharm.com, under the investor relations Investor relations The process by which the corporation communicates with its investors. section, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. About Arena Arena Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development and commercialization of drugs in four major therapeutic areas: metabolic diseases, cardiovascular diseases, central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency and inflammatory diseases. Arena is developing a broad pipeline of compounds including one in Phase I clinical trials Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I for obesity and another in preclinical development for insomnia. The company's compounds act on an important class of drug targets called G protein-coupled receptors G protein-coupled receptors (GPCRs), also known as seven transmembrane receptors, 7TM receptors, heptahelical receptors, and G protein linked receptors (GPLR , or GPCRs, and were developed using Arena's proprietary technologies, including CART(TM) (Constitutively Activated Receptor Technology) and Melanophore melanophore /mel·a·no·phore/ (-for?) a pigment cell containing melanin, especially such a cell in fishes, amphibians, and reptiles. mel·a·no·phore n. . Arena also has research collaborations with Merck, Fujisawa, Taisho and TaiGen for products in a number of different indications. For additional information about Arena, please visit their website at http://www.arenapharm.com. Certain statements in this press release are forward- looking statements that involve a number of risks and uncertainties. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Actual events or results may differ materially from Arena's expectations. Important factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's SEC reports, including Arena's most recent annual report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. . These forward-looking statements represent Arena's judgment as of the date of this release. Arena disclaims any intent or obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion